Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A8G6 SARS-CoV-2 neutralizing antibody combination nasal spray
- Development stage
- Unknown
- Lead developer
- Mingdao Haoyue Biotechnology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intranasal
01
Overview
A8G6 is a neutralizing antibody combination nasal spray developed for the prevention and treatment of COVID-19. It consists of two potent monoclonal antibodies, A8 and G6, which were identified and characterized by researchers at Chongqing Medical University. These antibodies target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, effectively blocking the virus's entry into host cells by preventing its interaction with the ACE2 receptor. The nasal spray formulation is designed to provide localized protection in the upper respiratory tract, serving both as a post-exposure prophylactic for healthy individuals and a treatment for patients with mild to moderate COVID-19. Clinical evaluation in China has focused on its safety, tolerability, and virologic efficacy.
- Other names
- A8G6 nasal sprayA-8G6 nasal sprayA 8G6 nasal sprayA8 + G6 antibody combinationA8/G6 nasal spray
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on A8G6 SARS-CoV-2 neutralizing antibody combination nasal spray.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on A8G6 SARS-CoV-2 neutralizing antibody combination nasal spray.